XML 37 R27.htm IDEA: XBRL DOCUMENT v3.8.0.1

Collaboration Agreements - Accounting for the AstraZeneca Agreements - Additional Information 3 (Detail) - AstraZeneca Agreements [Member]	3 Months Ended
	Mar. 31, 2018 USD ($)
Collaborative Arrangements and Non-collaborative Arrangement Transactions [Line Items]
Right-of-return provisions for delivered items	$ 0
Royalty rate against projected net revenues	40.00%
Discount rate applied	17.50%
Co-development services, currently estimated continuation year	2020
Manufacturing Commercial Supplies of Products [Member]
Collaborative Arrangements and Non-collaborative Arrangement Transactions [Line Items]
Manufacturing commercial supplies of products, revenue recognized	$ 0
U.S./RoW and China [Member]
Collaborative Arrangements and Non-collaborative Arrangement Transactions [Line Items]
Non-contingent upfront payments received	402,200,000
Variable consideration related to payments for milestones considered probable of being achieved	30,000,000
Variable consideration related to co-development billings	$ 682,200,000

X

- Definition

Co-development services, estimated continuation year.

+ References

No definition available.

+ Details

Name:	fgen_CoDevelopmentServicesEstimatedContinuationYear
Namespace Prefix:	fgen_
Data Type:	xbrli:gYearItemType
Balance Type:	na
Period Type:	duration

X

- Definition

Represents the amount of non-contingent upfront payments included under the collaborative agreement as arrangement consideration.

+ References

No definition available.

+ Details

Name:	fgen_ProceedsFromNonContingentUpfrontPayments
Namespace Prefix:	fgen_
Data Type:	xbrli:monetaryItemType
Balance Type:	debit
Period Type:	duration

X

- Definition

Implied royalty rate used to find the net present value of future cash flows.

+ References

No definition available.

+ Details

Name:	fgen_RoyaltyRateOnNetRevenue
Namespace Prefix:	fgen_
Data Type:	num:percentItemType
Balance Type:	na
Period Type:	instant

X

- Definition

Variable consideration payment received related to co-development billings.

+ References

No definition available.

+ Details

Name:	fgen_VariableConsiderationPaymentReceivedRelatedToCoDevelopmentBillings
Namespace Prefix:	fgen_
Data Type:	xbrli:monetaryItemType
Balance Type:	debit
Period Type:	duration

X

- Definition

Variable consideration payment received upon achievement of milestone.

+ References

No definition available.

+ Details

Name:	fgen_VariableConsiderationPaymentReceivedUponAchievementOfMilestone
Namespace Prefix:	fgen_
Data Type:	xbrli:monetaryItemType
Balance Type:	debit
Period Type:	duration

X

- Definition

Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.

+ References

No definition available.

+ Details

Name:	us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems
Namespace Prefix:	us-gaap_
Data Type:	xbrli:stringItemType
Balance Type:	na
Period Type:	duration

X

- Definition

Interest rate used to find the present value of an amount to be paid or received in the future as an input to measure fair value. For example, but not limited to, weighted average cost of capital (WACC), cost of capital, cost of equity and cost of debt.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 820
-SubTopic 10
-Section 50
-Paragraph 2
-Subparagraph (bbb)
-URI http://asc.fasb.org/extlink&oid=66048111&loc=d3e19207-110258

+ Details

Name:	us-gaap_FairValueInputsDiscountRate
Namespace Prefix:	us-gaap_
Data Type:	num:percentItemType
Balance Type:	na
Period Type:	duration

X

- Definition

Amount of revenue from the sale of manufactured products, classified as other.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 225
-SubTopic 10
-Section S99
-Paragraph 2
-Subparagraph (SX 210.5-03.1(a))
-URI http://asc.fasb.org/extlink&oid=63488584&loc=d3e20235-122688

+ Details

Name:	us-gaap_RevenueOtherManufacturedProducts
Namespace Prefix:	us-gaap_
Data Type:	xbrli:monetaryItemType
Balance Type:	credit
Period Type:	duration

X

- Definition

Amount of estimated sales returns.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 235
-SubTopic 10
-Section 50
-Paragraph 3
-URI http://asc.fasb.org/extlink&oid=84158767&loc=d3e18780-107790

Reference 2: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 605
-SubTopic 15
-Section 45
-Paragraph 1
-URI http://asc.fasb.org/extlink&oid=68051624&loc=d3e47468-111626

+ Details

Name:	us-gaap_RevenueRecognitionSalesReturnsReserveForSalesReturns
Namespace Prefix:	us-gaap_
Data Type:	xbrli:monetaryItemType
Balance Type:	credit
Period Type:	duration

X

- Details

Name:	us-gaap_TypeOfArrangementAxis=fgen_AstraZenecaAgreementsMember
Namespace Prefix:
Data Type:	na
Balance Type:
Period Type:

X

- Details

Name:	us-gaap_ProductOrServiceAxis=fgen_ManufacturingCommercialSuppliesOfProductsMember
Namespace Prefix:
Data Type:	na
Balance Type:
Period Type:

X

- Details

Name:	us-gaap_StatementGeographicalAxis=fgen_UnitedStatesAndRestOfWorldAndChinaMember
Namespace Prefix:
Data Type:	na
Balance Type:
Period Type: